Pfizer (NYSE:PFE) Stock Price Down 0.7% – Should You Sell?

Pfizer Inc. (NYSE:PFE)’s stock price traded down 0.7% during mid-day trading on Monday . The company traded as low as $26.02 and last traded at $26.09. 9,528,568 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 36,541,645 shares. The stock had previously closed at $26.28.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s fifty day moving average price is $26.14 and its 200 day moving average price is $27.00. The company has a market cap of $144.96 billion, a PE ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Trading of Pfizer

Hedge funds have recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $28,000. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.